Lipocine reports Q3 2026 results, highlights BLOOM study launch for LPCN 1154
The company started its Phase 3 BLOOM trial in postpartum depression in September 2026 and reported $28.5 million in cash as of November 4, 2026.
Lipocine Inc. announced financial results for the third quarter ended September 30, 2026, alongside a corporate update dated November 5, 2026.
In September 2026, the company announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study.1 The trial is a Phase 3 placebo-controlled outpatient study expected to enroll approximately 120 participants with postpartum depression, designed to generate prospective efficacy and safety evidence to support a potential New Drug Application under the 505(b)(2) pathway.1 Lipocine said feedback from a recent FDA meeting, including the necessity of a positive and well-controlled Phase 3 trial, together with learnings from the prior Phase 3 trial, were incorporated into the BLOOM study design.1 The company also noted that FDA feedback acknowledged the NDA submission package presented appears complete to support a 505(b)(2) submission, aside from the need for one positive and well-controlled Phase 3 trial.1 Lipocine said it continues to look for partners to help develop, win approval for, and bring BRLIZIO (LPCN 1154) to market.
On other neuroactive steroid programs, Lipocine said it plans to submit a Phase 2 protocol to the FDA for LPCN 2201 in major depressive disorder following planned clinical assessment of unique oral brexanolone formulations, and may initiate a study subject to resource prioritization.1 For LPCN 2203 in essential tremor, the company has completed oral pharmacokinetic studies and plans to submit a protocol for a proof-of-concept Phase 2 study to the FDA, with any future studies subject to resource prioritization.1
On TLANDO, Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism in September 2026,1 with Verity Pharma, Lipocine's North American partner, planning a Canadian launch in early 2027.1 Separately, Lipocine's distribution partner Pharmalink received marketing authorization in the United Arab Emirates for TESTYRA (TLANDO) in July 2026,1 with launch planned in the UAE in early 2027.1
On finances, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities as of September 30, 2026, compared to $14.9 million at December 31, 2025.1 As of November 4, 2026, the company had approximately $28.5 million of unrestricted cash, cash equivalents and marketable investment securities.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.